Rapid Dose Therapeutics Corp. RDTCF
OTC PK
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 425.50K | 480.70K | 470.70K | 490.60K | 556.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 425.50K | 480.70K | 470.70K | 490.60K | 556.70K |
| Cost of Revenue | 198.50K | 273.20K | 248.80K | 216.10K | 278.10K |
| Gross Profit | 227.00K | 207.50K | 221.90K | 274.40K | 278.60K |
| SG&A Expenses | 305.30K | 429.50K | 613.40K | 557.40K | 552.30K |
| Depreciation & Amortization | 87.60K | 85.80K | 90.70K | 98.60K | 95.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 591.20K | 798.00K | 963.80K | 886.30K | 915.20K |
| Operating Income | -165.80K | -317.30K | -493.10K | -395.70K | -358.50K |
| Income Before Tax | -366.60K | -509.40K | -816.90K | -601.80K | -514.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -366.60K | -509.40K | -816.90K | -601.80K | -514.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -366.60K | -509.40K | -816.90K | -601.80K | -514.70K |
| EBIT | -165.80K | -317.30K | -493.10K | -395.70K | -358.50K |
| EBITDA | -140.40K | -286.10K | -470.00K | -365.90K | -263.30K |
| EPS Basic | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 136.34M | 136.78M | 131.68M | 82.55M | 131.38M |
| Average Diluted Shares Outstanding | 136.34M | 136.78M | 131.68M | 82.55M | 131.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |